gp100-derived peptide epitopes presented by HLA-A*0201 (gp100/HLA-A*02:01)

gp100-derived peptide epitopes presented by HLA-A*0201 are specific molecular complexes consisting of fragments from the Melanocyte protein PMEL (gp100) bound to the Human Leukocyte Antigen A*0201 molecule. These complexes are primarily expressed on the surface of melanocytes and melanoma cells, serving as critical targets for T-cell mediated immune recognition (UniProt: P40967). In malignant cells, the overexpression of gp100 makes these peptide-MHC complexes ideal targets for cancer immunotherapies, particularly in patients carrying the HLA-A*0201 allele (Nathan et al., 2021, NEJM). Therapeutic agents like Tebentafusp, a first-in-class bispecific T-cell engager, are designed to recognize this specific complex and redirect cytotoxic T-cells to eliminate melanoma cells (FDA, 2022). Additionally, peptide-based vaccines and TCR-engineered T-cell therapies have been developed to enhance the immune system's ability to detect these specific epitopes. However, because gp100 is also expressed in healthy melanocytes in the skin, eye, and ear, targeting this complex can lead to on-target, off-tumor toxicities such as vitiligo and ocular inflammation. Clinical efficacy is strictly dependent on the patient's HLA status, making HLA-A*0201 a mandatory predictive biomarker for associated therapies.

Other names

PMEL peptide/HLA-A*02:01 complexgp100:209-217(210M)/HLA-A2Melanocyte protein PMEL epitopesgp100/HLA-A2 complexgp100:154-162 epitope

Drugs targeting this complex typically function as bispecific T-cell engagers (ImmTACs) that bridge the peptide-MHC complex with CD3 on T-cells, or as vaccines that stimulate the expansion of endogenous CD8+ T-cells specific to the gp100 epitope.